Efficacy of Nigella sativa seeds oil in patients with Behcet’s disease: a double-blind randomized controlled trial | ||
| Avicenna Journal of Phytomedicine | ||
| مقاله 4، دوره 8، شماره 6، بهمن و اسفند 2018، صفحه 498-503 اصل مقاله (540.35 K) | ||
| نوع مقاله: Short communication | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2018.11101 | ||
| نویسندگان | ||
| Hadiseh Kavandi1؛ Mehrzad Hajialilo1؛ Alireza Khabbazi* 2 | ||
| 1Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran | ||
| 2Connective Tissue Research Center, Tabriz University of Medical Sciences, Tabriz, Iran | ||
| چکیده | ||
| Objective: Nigella sativa (NS) is a herbal medicine with anti-inflammatory and anti-oxidant functions. This study was designed to evaluate the effect of oral administration of NS seeds oil on the treatment of Behcet’s disease (BD). Materials and methods:In this double-blind randomized controlled study, 130 patients with BD were screened and 71 patients with BD were randomly allocated to the treatment (n=37) and control (n=34) groups. Finally, 32 and 30 patients in the treatment and control groups, respectively, completed the study.The study protocol was registered in the Iranian Registry of Clinical Trials (IRCT) with registration No. IRCT201511086975N5. Treatment and control groups received soft gels containing 1000 mg NS oil or 1000 mg placebo per day for 12 months, respectively. Disease activity using the Iranian Behcet’s disease dynamic activity measure (IBDDAM), total inflammatory activity index (TIAI) and Behcet’s disease current activity form (BDCAF) were evaluated in all patients before initiation of the trial and every 2 months, for 12 months. Results: Disease activity decreased in the study groups; difference between the two groups was not significant. No serious adverse events were seen in the treatment and control groups. Conclusion: NS oil at the dose of 1000 mg/day is not effective in controlling BD activity. | ||
| کلیدواژهها | ||
| Behcet's disease؛ Nigella Sativa؛ Iranian Behcet’s disease dynamic activity measure (IBDDAM)؛ Behcet’s disease current activity form (BDCAF) | ||
| مراجع | ||
|
Abdali S. 2009. Topical Nigella Sativa in the treatment of oro-genital ulceration in Behcet's disease, MDJ. 6: 366-370.
Alipour S, Nouri M, Sakhinia E, Samadi N, Roshanravan N, Ghavami A, Khabbazi A. 2017. Epigenetic alterations in chronic disease focusing on Behcet’s disease: Review. Biomed Pharmacother, 91: 526-533.
Bhakta B, Brennan P, James T, Chamberlain M, Noble B, Silman A. 1999. Behcet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology, 38: 728–733.
Budancamanak M, Kanter M, Demirel A, Ocakci A, Uysal H, Karakaya C. 2006. Protective effects of thymoquinone and methotrexate on the renal injury incollagen-induced arthritis. Arch Toxicol, 80: 768–776.
Davatchi F, Akbarian M, Shahram F, Tebbi M, Chams C, Chams H. 1991. Iran Behcet’s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology. Hungarian Rheumatol, 134 (abstract FP10–100).
Davatchi F, Jamshidi AR, Tehrani Bani-Hashemi A, Gholami J, Forouzanfar MH, Moradi M, Akhlaghi M, khabbazi A, Salari AH, Salessi M, Karimifar M, Essalat-manesh K, Hadj-aliloo M, Arabzadeh B, Alipour B, Shahram F and Nadji A. 2007. Prevalence of Behcet’s disease in Iran: a WHOILAR COPCORD stage I study. APLAR J Rheumatol, 10: 239–243.
Dehghanzadeh R, Babaloo Z, Sakhinia E, Khabazi A, Shanehbandi D, Sadigh-Eteghad S, Gharibi T. 2016. IL-27 Gene Polymorphisms in Iranian Patients with Behcet’s Disease. Clin Lab, 62: 855-861.
De Smet MD, Dayan M. 2000. Prospective determination of T-cell responses to S-antigen in Behcet’s disease patients and controls. Invest Ophthalmol Vis Sci, 41: 3480–3484.
Doğan P, Tanrikulu G, Soyuer U, Köse K. 1994. Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin and copper levels in Behcet’s disease. Clin Biochem, 27: 413-418.
Esmaeili M, Bonyadi M, Khabbazi A, Ebrahimi AA, Sharif SK, Hajialilo M, Kolahi S, Dastgiri S. 2011. Common MEFV mutations in Iranian Azeri Turkish patients with Behcet’s disease. Scand J Rheumatol, 40: 383-386.
Fortune F, Walker J, Lehner T. 1990. The expression of γδ T cell receptor and prevalence of primed, activated and IgA-bound T cells in Behcet’s syndrome. Clin Exp Immunol, 82: 326-332.
Gheita TA, Kenawy SA. 2012. Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study. Phytother Res, 26: 1246-1248.
Hadi V, Kheirouri S, Alizadeh M, Khabbazi A, Hosseini H. 2016. Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Avicenna J Phytomed, 6: 34-43.
International Team for the Revision of the International Criteria for Behcet’s Disease (ITR-ICBD). 2014. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol, 28: 338–347.
Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S. 2014. Demographic and clinical features of Behcet’s disease in Azerbaijan. Int J Rheum, Epub ahead of print.
Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A, Hajialiloo M, Ghojazadeh M, Taei R, Kolahi S. 2014. The status of serum vitamin D in patients with active Behcet’s disease compared with controls. Int J Rheum Dis, 17: 430-434.
Kheirouri S, Hadi V. 2016. Immunomodulatory Effect of Nigella sativa Oil on T Lymphocytes in Patients with Rheumatoid Arthritis. Immunol Invest. 45: 271-283.
Kolahi S, Khabbazi A, Khodadadi H, Estiar MA, Hajialiloo M, Emrahi L, Sakhinia E. 2015. Vitamin D receptor gene polymorphisms in Iranian patients with Bechet disease. Scand J Rheumatol, 44: 163-167.
Köse K, Doğan P, Aşçioğlu M, Erkiliç K, Aşçioğlu O. 1995. Oxidative stress and antioxidant defenses in plasma of patients with Behcet’s disease. Tohoku J Exp Med, 176: 239-248.
Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, Lhote F, Ramanoelina J, Coste J, Guillevin L. 2008. Population based prevalence study of Behcet’s disease. Differences by ethnic origin and low variation by age at immigration. Arthritis Rheum, 58: 3951–3959.
Mazzoccoli G, Matarangolo A, Rubino R, Inglese M, De Cata A. 2016. Behcet’s syndrome: from pathogenesis to novel therapies. Clin Exp Med, 16: 1-12.
Sara Darakhshana, Ali Bidmeshki Poura, Abasalt Hosseinzadeh Colagar, Sajjad Sisakhtnezhad. 2015. Thymoquinone and its therapeutic potentials. Pharmacol Res, 96: 138-158
Sayed-Ahmed MM, Aleisa AM, Al-Rejaie SS, Al-Yahya AA, Al-Shabanah OA, Hafez MM, Nagi MN. 2010. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid Med Cell Longev, 3: 254–261
Schleicher P, Saleh M. 2000. Black cumin: the magical Egyptian herb for allergies, asthma, and immune disorders. In: Rochester, Vermont Healing Arts Press, pp. 90, Inner Traditions/Bear & Co.
Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. 2009. Comparison of existing disease activity indices in the follow-up of patients with Behcet’s disease. Mod Rheumatol, 19: 536–541.
Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. 2004. Increased peripheral blood γδ T cells and natural killer cells in Behcet’s disease. J Rheumatol, 19: 588-592.
Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. 1993. Cellular autoimmunity to retinal specific antigens in patients with Behcet’s disease. Br J Ophthalmol, 77: 584 –589.
| ||
|
آمار تعداد مشاهده مقاله: 26,980 تعداد دریافت فایل اصل مقاله: 12,069 |
||